Monoprost (Latanoprost)

Latanoprost activates prostaglandin F‑type receptors in the eye, which remodels the extracellular matrix of the ciliary body. This remodeling enhances uveoscleral outflow of aqueous humor, thereby decreasing intra‑ocular pressure.

The prescribed regimen is determined by the treating ophthalmologist. Typically, one drop is instilled into the affected eye(s) once daily, usually in the evening, but the exact dose and timing are individualized.

Safety data for latanoprost in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by the prescriber.

To request Monoprost, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with beta‑blocker eye drops such as timolol, latanoprost generally provides greater IOP reduction with once‑daily dosing and a different side‑effect profile. Among prostaglandin analogs, its efficacy is similar to bimatoprost and travoprost, while tolerability may vary per patient.

Monoprost should be stored at room temperature, below 25 °C, in its original packaging. Protect the bottle from moisture and direct sunlight. Do not freeze the product, and keep the dropper tip clean to avoid contamination.

Monoprost is applied topically to the eye. The patient tilts the head back, pulls down the lower eyelid to form a pocket, and instills one drop into the conjunctival sac of the prescribed eye(s). The medication is usually given in the evening.

Serious risks include severe allergic reactions, uveitis, macular edema (particularly in diabetic patients), paradoxical increase in intra‑ocular pressure, and corneal complications such as thinning or ulceration. Patients should seek immediate medical attention if they experience pain, vision loss or marked redness.

Monoprost is contraindicated in individuals with known hypersensitivity to latanoprost or any excipients, and in patients with active ocular inflammation or infection. Caution is also advised for those with a history of herpetic eye disease or corneal disorders.